Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Consensus Price Target of $107.44 According to Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus recommendation of “Hold” by the fourteen brokerages that are covering the stock, Marketbeat reports. Eleven investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $107.44.

Several equities analysts have weighed in on the stock. William Blair set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. Mizuho lowered shares of Lantheus from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $115.00 to $109.00 in a research report on Tuesday, October 13th. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Leerink Partners set a $102.50 target price on Lantheus in a report on Monday, August 3rd.

Institutional Trading of Lantheus

A number of large investors have recently modified their holdings of the company. Jupiter Topco LLC acquired a new stake in shares of Lantheus in the second quarter valued at approximately $575,628,000. Assenagon Asset Management S.A. raised its stake in Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after acquiring an additional 582,661 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after acquiring an additional 522,678 shares during the period. Summit Street Capital Management LLC bought a new position in shares of Lantheus in the second quarter worth $44,454,000. Finally, Defilade Capital Management L.P. bought a new position in shares of Lantheus in the first quarter worth $18,917,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $100.46 on Monday. Lantheus has a 1-year low of $50.15 and a 1-year high of $111.86. The company has a market cap of $6.56 billion, a price-to-earnings ratio of 24.27 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The stock has a 50 day simple moving average of $100.26 and a 200-day simple moving average of $91.17.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the prior year, the company posted $1.57 earnings per share. Lantheus’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts expect that Lantheus will post 4.54 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.